kyselina acetylsalicylová sanofi 0,5g prášek a rozpouštědlo pro injekční roztok
sanofi s.r.o., praha array - 4151 racemickÝ lysin-acetylsalicylÁt - prášek a rozpouštědlo pro injekční roztok - 0,5g - kyselina acetylsalicylovÁ
ketonal prolong 100mg tableta s prodlouženým uvolňováním
sandoz s.r.o., praha array - 2872 ketoprofen - tableta s prodlouženým uvolňováním - 100mg - ketoprofen
okitask 25mg obalené granule v sáčku
dompé farmaceutici s.p.a., milano array - 18557 ketoprofen-lysin - obalené granule v sáčku - 25mg - ketoprofen
okitask 25mg potahovaná tableta
dompé farmaceutici s.p.a., milano array - 18557 ketoprofen-lysin - potahovaná tableta - 25mg - ketoprofen
skudexa 75mg/25mg granule pro perorální roztok v sáčku
menarini international operations luxembourg s.a., luxembourg array - 2719 tramadol-hydrochlorid; 16261 dexketoprofen-trometamol - granule pro perorální roztok v sáčku - 75mg/25mg - tramadol a dexketoprofen
skudexa 75mg/25mg potahovaná tableta
menarini international operations luxembourg s.a., luxembourg array - 2719 tramadol-hydrochlorid; 16261 dexketoprofen-trometamol - potahovaná tableta - 75mg/25mg - tramadol a dexketoprofen
portrazza
eli lilly nederland b.v. - necitumumab - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - portrazza v kombinaci s chemoterapií gemcitabinu a cisplatiny je indikován k léčbě dospělých pacientů s receptorem lokálně pokročilého nebo metastatického epidermální růstový faktor (egfr) vyjádření skvamózní nemalobuněčný karcinom plic není předchozí chemoterapii pro tuto podmínku.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
imfinzi
astrazeneca ab - durvalumab - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastická činidla - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.